Exemptions from certain requirements under section 582 of the FD&C Act granted to small business dispensers until November 27, 2027.
These exemptions alleviate the regulatory burden on small dispensers, ensuring patient access to medications while allowing additional time for compliance assessments.
Small business dispensers are encouraged to complete a mandatory assessment survey by September 22, 2026, and do not need to submit information to the FDA while utilizing these exemptions.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Small business dispensers are encouraged to complete a mandatory assessment survey by September 22, 2026, and do not need to submit information to the FDA while utilizing these exemptions.
The FDA has issued exemptions from specific requirements of section 582 of the FD&C Act for small business dispensers, valid until November 27, 2027. This change allows time for these dispensers to complete an assessment and facilitates compliance adaptations for those with 25 or fewer full-time employees.
What changed: Exemptions from certain requirements under section 582 of the FD&C Act granted to small business dispensers until November 27, 2027.
Why it matters: These exemptions alleviate the regulatory burden on small dispensers, ensuring patient access to medications while allowing additional time for compliance assessments.
Practical implication: Small business dispensers are encouraged to complete a mandatory assessment survey by September 22, 2026, and do not need to submit information to the FDA while utilizing these exemptions.
Published from the regulator source ingestion pipeline after PV impact triage.
Initiate the update of labeling materials for Rasonque to reflect the new FDA approval and ensure compliance with reporting requirements for newly approved therapies.
Healthcare professionals must include daraxonrasib in adverse event reporting as the new treatment option is now available for eligible patients.
Affected healthcare facilities should remove all Automated Impella Controllers from use and stock, ensure annual preventive maintenance is followed, and report any adverse reactions to Abiomed or MedWatch.
Facilities using these devices must immediately cease their use, segregate them from other stock, and return them to Boston Scientific. Relevant personnel must be notified of this recall.
